Skip to main content
Fig. 3 | Systematic Reviews

Fig. 3

From: Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials

Fig. 3

a Evidence network for HBeAg loss for HBeAg-positive patients. b Evidence network for HBeAg seroconversion for HBeAg-positive patients. ADV adefovir 10 mg daily, ADV2 adefovir 30 mg daily, ETV entecavir, LAM lamivudine, TBV telbivudine, PLA placebo, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate; ADVTBV, ETVTDF, LAMADV, LAMADV1, LAMADV2, and LAMTBV code for different combinations of antiviral agents with full details in Additional file 3

Back to article page

Systematic Reviews

ISSN: 2046-4053